Epigenetic markers of prostate cancer in plasma circulating DNA

Rene Cortese, Andrew Kwan, Emilie Lalonde, Olga Bryzgunova, Anna Bondar, Ying Wu, Juozas Gordevicius, Mina Park, Gabriel Oh, Zachary A Kaminsky, Justina Tverkuviene, Arvydas Laurinavicius, Feliksas Jankevicius, Dorota H S Sendorek, Syed Haider, Sun Chong Wang, Sonata Jarmalaite, Pavel Laktionov, Paul C. Boutros, Arturas Petronis

Research output: Contribution to journalArticle

Abstract

Epigenetic differences are a common feature of many diseases, including cancer, and disease-associated changes have even been detected in bodily fluids. DNA modification studies in circulating DNA (cirDNA) may lead to the development of specific non-invasive biomarkers. To test this hypothesis, we investigated cirDNA modifications in prostate cancer patients with locally confined disease (n = 19), in patients with benign prostate hyperplasias (n = 20) and in men without any known prostate disease (n = 20). This initial discovery screen identified 39 disease-associated changes in cirDNA modification, and seven of these were validated using the sodium bisulfite-based mapping of modified cytosines in both the discovery cohort and an independent 38-patient validation cohort. In particular, we showed that the DNA modification of regions adjacent to the gene encoding ring finger protein 219 distinguished prostate cancer from benign hyperplasias with good sensitivity (61%) and specificity (71%). We also showed that repetitive sequences detected in this study were meaningful, as they indicated a highly statistically significant loss of DNA at the pericentromeric region of chromosome 10 in prostate cancer patients (p = 1.8 × 10-6). Based on these strong univariate results, we applied machine-learning techniques to develop a multi-locus biomarker that correctly distinguished prostate cancer samples from unaffected controls with 72% accuracy. Lastly, we used systems biology techniques to integrate our data with publicly available DNA modification and transcriptomic data from primary prostate tumors, thereby prioritizing genes for further studies. These data suggest that cirDNA epigenomics are promising source for non-invasive biomarkers.

Original languageEnglish (US)
Article numberdds192
Pages (from-to)3619-3631
Number of pages13
JournalHuman Molecular Genetics
Volume21
Issue number16
DOIs
StatePublished - Aug 2012
Externally publishedYes

Fingerprint

Epigenomics
Prostatic Neoplasms
DNA
Prostate
Biomarkers
Hyperplasia
Chromosomes, Human, Pair 10
Systems Biology
Nucleic Acid Repetitive Sequences
Cytosine
Genes
Fingers
Neoplasms
Sensitivity and Specificity
Proteins

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)
  • Molecular Biology

Cite this

Cortese, R., Kwan, A., Lalonde, E., Bryzgunova, O., Bondar, A., Wu, Y., ... Petronis, A. (2012). Epigenetic markers of prostate cancer in plasma circulating DNA. Human Molecular Genetics, 21(16), 3619-3631. [dds192]. https://doi.org/10.1093/hmg/dds192

Epigenetic markers of prostate cancer in plasma circulating DNA. / Cortese, Rene; Kwan, Andrew; Lalonde, Emilie; Bryzgunova, Olga; Bondar, Anna; Wu, Ying; Gordevicius, Juozas; Park, Mina; Oh, Gabriel; Kaminsky, Zachary A; Tverkuviene, Justina; Laurinavicius, Arvydas; Jankevicius, Feliksas; Sendorek, Dorota H S; Haider, Syed; Wang, Sun Chong; Jarmalaite, Sonata; Laktionov, Pavel; Boutros, Paul C.; Petronis, Arturas.

In: Human Molecular Genetics, Vol. 21, No. 16, dds192, 08.2012, p. 3619-3631.

Research output: Contribution to journalArticle

Cortese, R, Kwan, A, Lalonde, E, Bryzgunova, O, Bondar, A, Wu, Y, Gordevicius, J, Park, M, Oh, G, Kaminsky, ZA, Tverkuviene, J, Laurinavicius, A, Jankevicius, F, Sendorek, DHS, Haider, S, Wang, SC, Jarmalaite, S, Laktionov, P, Boutros, PC & Petronis, A 2012, 'Epigenetic markers of prostate cancer in plasma circulating DNA', Human Molecular Genetics, vol. 21, no. 16, dds192, pp. 3619-3631. https://doi.org/10.1093/hmg/dds192
Cortese R, Kwan A, Lalonde E, Bryzgunova O, Bondar A, Wu Y et al. Epigenetic markers of prostate cancer in plasma circulating DNA. Human Molecular Genetics. 2012 Aug;21(16):3619-3631. dds192. https://doi.org/10.1093/hmg/dds192
Cortese, Rene ; Kwan, Andrew ; Lalonde, Emilie ; Bryzgunova, Olga ; Bondar, Anna ; Wu, Ying ; Gordevicius, Juozas ; Park, Mina ; Oh, Gabriel ; Kaminsky, Zachary A ; Tverkuviene, Justina ; Laurinavicius, Arvydas ; Jankevicius, Feliksas ; Sendorek, Dorota H S ; Haider, Syed ; Wang, Sun Chong ; Jarmalaite, Sonata ; Laktionov, Pavel ; Boutros, Paul C. ; Petronis, Arturas. / Epigenetic markers of prostate cancer in plasma circulating DNA. In: Human Molecular Genetics. 2012 ; Vol. 21, No. 16. pp. 3619-3631.
@article{4504db3b89ba4e83a54876afc69ec11e,
title = "Epigenetic markers of prostate cancer in plasma circulating DNA",
abstract = "Epigenetic differences are a common feature of many diseases, including cancer, and disease-associated changes have even been detected in bodily fluids. DNA modification studies in circulating DNA (cirDNA) may lead to the development of specific non-invasive biomarkers. To test this hypothesis, we investigated cirDNA modifications in prostate cancer patients with locally confined disease (n = 19), in patients with benign prostate hyperplasias (n = 20) and in men without any known prostate disease (n = 20). This initial discovery screen identified 39 disease-associated changes in cirDNA modification, and seven of these were validated using the sodium bisulfite-based mapping of modified cytosines in both the discovery cohort and an independent 38-patient validation cohort. In particular, we showed that the DNA modification of regions adjacent to the gene encoding ring finger protein 219 distinguished prostate cancer from benign hyperplasias with good sensitivity (61{\%}) and specificity (71{\%}). We also showed that repetitive sequences detected in this study were meaningful, as they indicated a highly statistically significant loss of DNA at the pericentromeric region of chromosome 10 in prostate cancer patients (p = 1.8 × 10-6). Based on these strong univariate results, we applied machine-learning techniques to develop a multi-locus biomarker that correctly distinguished prostate cancer samples from unaffected controls with 72{\%} accuracy. Lastly, we used systems biology techniques to integrate our data with publicly available DNA modification and transcriptomic data from primary prostate tumors, thereby prioritizing genes for further studies. These data suggest that cirDNA epigenomics are promising source for non-invasive biomarkers.",
author = "Rene Cortese and Andrew Kwan and Emilie Lalonde and Olga Bryzgunova and Anna Bondar and Ying Wu and Juozas Gordevicius and Mina Park and Gabriel Oh and Kaminsky, {Zachary A} and Justina Tverkuviene and Arvydas Laurinavicius and Feliksas Jankevicius and Sendorek, {Dorota H S} and Syed Haider and Wang, {Sun Chong} and Sonata Jarmalaite and Pavel Laktionov and Boutros, {Paul C.} and Arturas Petronis",
year = "2012",
month = "8",
doi = "10.1093/hmg/dds192",
language = "English (US)",
volume = "21",
pages = "3619--3631",
journal = "Human Molecular Genetics",
issn = "0964-6906",
publisher = "Oxford University Press",
number = "16",

}

TY - JOUR

T1 - Epigenetic markers of prostate cancer in plasma circulating DNA

AU - Cortese, Rene

AU - Kwan, Andrew

AU - Lalonde, Emilie

AU - Bryzgunova, Olga

AU - Bondar, Anna

AU - Wu, Ying

AU - Gordevicius, Juozas

AU - Park, Mina

AU - Oh, Gabriel

AU - Kaminsky, Zachary A

AU - Tverkuviene, Justina

AU - Laurinavicius, Arvydas

AU - Jankevicius, Feliksas

AU - Sendorek, Dorota H S

AU - Haider, Syed

AU - Wang, Sun Chong

AU - Jarmalaite, Sonata

AU - Laktionov, Pavel

AU - Boutros, Paul C.

AU - Petronis, Arturas

PY - 2012/8

Y1 - 2012/8

N2 - Epigenetic differences are a common feature of many diseases, including cancer, and disease-associated changes have even been detected in bodily fluids. DNA modification studies in circulating DNA (cirDNA) may lead to the development of specific non-invasive biomarkers. To test this hypothesis, we investigated cirDNA modifications in prostate cancer patients with locally confined disease (n = 19), in patients with benign prostate hyperplasias (n = 20) and in men without any known prostate disease (n = 20). This initial discovery screen identified 39 disease-associated changes in cirDNA modification, and seven of these were validated using the sodium bisulfite-based mapping of modified cytosines in both the discovery cohort and an independent 38-patient validation cohort. In particular, we showed that the DNA modification of regions adjacent to the gene encoding ring finger protein 219 distinguished prostate cancer from benign hyperplasias with good sensitivity (61%) and specificity (71%). We also showed that repetitive sequences detected in this study were meaningful, as they indicated a highly statistically significant loss of DNA at the pericentromeric region of chromosome 10 in prostate cancer patients (p = 1.8 × 10-6). Based on these strong univariate results, we applied machine-learning techniques to develop a multi-locus biomarker that correctly distinguished prostate cancer samples from unaffected controls with 72% accuracy. Lastly, we used systems biology techniques to integrate our data with publicly available DNA modification and transcriptomic data from primary prostate tumors, thereby prioritizing genes for further studies. These data suggest that cirDNA epigenomics are promising source for non-invasive biomarkers.

AB - Epigenetic differences are a common feature of many diseases, including cancer, and disease-associated changes have even been detected in bodily fluids. DNA modification studies in circulating DNA (cirDNA) may lead to the development of specific non-invasive biomarkers. To test this hypothesis, we investigated cirDNA modifications in prostate cancer patients with locally confined disease (n = 19), in patients with benign prostate hyperplasias (n = 20) and in men without any known prostate disease (n = 20). This initial discovery screen identified 39 disease-associated changes in cirDNA modification, and seven of these were validated using the sodium bisulfite-based mapping of modified cytosines in both the discovery cohort and an independent 38-patient validation cohort. In particular, we showed that the DNA modification of regions adjacent to the gene encoding ring finger protein 219 distinguished prostate cancer from benign hyperplasias with good sensitivity (61%) and specificity (71%). We also showed that repetitive sequences detected in this study were meaningful, as they indicated a highly statistically significant loss of DNA at the pericentromeric region of chromosome 10 in prostate cancer patients (p = 1.8 × 10-6). Based on these strong univariate results, we applied machine-learning techniques to develop a multi-locus biomarker that correctly distinguished prostate cancer samples from unaffected controls with 72% accuracy. Lastly, we used systems biology techniques to integrate our data with publicly available DNA modification and transcriptomic data from primary prostate tumors, thereby prioritizing genes for further studies. These data suggest that cirDNA epigenomics are promising source for non-invasive biomarkers.

UR - http://www.scopus.com/inward/record.url?scp=84865099717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865099717&partnerID=8YFLogxK

U2 - 10.1093/hmg/dds192

DO - 10.1093/hmg/dds192

M3 - Article

C2 - 22619380

AN - SCOPUS:84865099717

VL - 21

SP - 3619

EP - 3631

JO - Human Molecular Genetics

JF - Human Molecular Genetics

SN - 0964-6906

IS - 16

M1 - dds192

ER -